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Abstract We discuss the analytic and practical consider-
ations in a large case–control study that had two control
groups; the first control group consisting of partners of
patients and the second obtained by random digit dialling
(RDD). As an example of the evaluation of a general life-
style factor, we present body mass index (BMI). Both con-
trol groups had lower BMIs than the patients. The
distribution in the partner controls was closer to that of the
patients, likely due to similar lifestyles. A statistical
approach was used to pool the results of both analyses,
wherein partners were analyzed with a matched analysis,
while RDDs were analyzed without matching. Even with a
matched analysis, the odds ratio with partner controls
remained closer to unity than with RDD controls, which is
probably due to unmeasured confounders in the comparison
with the random controls as well as intermediary factors.
However, when studying injuries as a risk factor, the odds
ratio remained higher with partner control subjects than with
RRD control subjects, even after taking the matching into
account. Finally we used factor V Leiden as an example of a
genetic risk factor. The frequencies of factor V Leiden were
identical in both control groups, indicating that for the
analyses of this genetic risk factor the two control groups
could be combined in a single unmatched analysis. In con-
clusion, the effect measures with the two control groups
were in the same direction, and of the same order of mag-
nitude. Moreover, it was not always the same control group
that produced the higher or lower estimates, and a matched
analysis did not remedy the differences. Our experience
with the intricacies of dealing with two control groups may
be useful to others when thinking about an optimal research
design or the best statistical approach.
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Introduction
When designing a case–control study an important decision
is the choice of the appropriate control group. The general
requirement is that the control group should reflect the
exposure frequency in the source population of the cases [1,
2]. Still, various practical solutions exist. Control subjects
can be selected randomly from the general population, or can
be partners, friends or neighbours of the patient. Another
source of control subjects is the hospital in which cases are
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hospitalized. There are advantages and disadvantages for
each choice. For example, random population control sub-
jects may be more difficult to locate and less motivated to
take part in the study than patient-related control subjects
such as partners, friends, neighbours or (unaffected) family
members. Asking patient-related control subjects as control
subjects has the risk of overmatching on the study exposure
because of joint exposures [3]. Population control subjects
potentially have the drawback of recall bias and selective
participation; their motivation to recall past events is likely to
be different from that of cases [3]. Hospital control subjects
are readily accessible, usually cooperative and more likely to
have the same recall ability as the cases, but always pose the
problem whether exposure is unrelated to the disease leading
to the hospitalization of the control [3].
Situations arise in which the investigator may consider to
include two or more control groups. On one hand, the use of
multiple control groups could lead to inconsistent results
with the different control groups, and proper analysis may
become complex [1]. On the other hand, when different types
of research questions are addressed and adjustment for dif-
ferent variables is required, multiple control groups might be
useful.
In the Multiple Environmental and Genetic Assessment
of risk factors for venous thrombosis (MEGA study), a
very large population-based case–control study, we ini-
tially included partners of patients as control subjects
because the main focus of the study was on genetic risk
factors for venous thrombosis and their interaction with
environmental and lifestyle factors. It seemed unlikely that
partners would select each other based on similarities in
genetic risk factors for venous thrombosis.
We also expected that asking partners would make it
easier to recruit control subjects with malignancies, preg-
nancy, or chronic diseases, which was necessary if we
wanted to study these diseases in relation to the risk of
venous thrombosis. However, as a result of selecting
partners of patients, who usually are of the opposite sex,
the age-sex distribution of the partner controls showed
some peculiarities. In particular, there was only a small
group of young men with venous thrombosis, while there
was a relatively large group of young women with venous
thrombosis (due to pregnancy and oral contraceptive use).
The small group of young men yielded an even smaller
control group of young female partners, which made
women-specific risk factors difficult to analyze, due to a
relative lack of control subjects. Moreover, not all patients
had a partner, so there were less available partners than
patients, and in addition individuals with a partner may be
different than those without a partner [1]. To remedy the
case–control imbalance and to boost statistical power, we
included an additional population control group that would
be useful for certain analyses (such as pregnancy in young
women), and increased the overall numbers for the genetic
analyses (in particular for interactions)—as no differences
in genetic make-up between partner control subjects and
population control subjects were expected.
Although the odds ratios for all studied risk factors were
in the same direction, and of similar order of magnitude
with the two control groups, the point estimates differed
somewhat, in particular for life-style variables. This rep-
resented a challenge of coming to the optimal combination
of the information from the two control groups. In this
paper, we describe how we proceeded.
MEGA study
Patients and partners
Between March 1999 and September 2004, we included
consecutive patients with a first diagnosis of venous throm-
bosis. Patients were selected from the files of six large
anticoagulation clinics in the Netherlands, which monitor
anticoagulation treatment in all patients in a geographically
well-defined area. Patients between the age of 18 and 70 with
deep venous thrombosis of the leg, pulmonary embolism or a
combination of these diagnoses were included. Patients with
severe psychiatric problems or those unable to speak Dutch
were considered as ineligible for practical reasons.
During the inclusion period, partners of patients were
asked to participate as control subjects. Only partner con-
trol subjects between the age of 18 and 70 without a history
of deep venous thrombosis were included and the same
exclusion criteria were applied as for patients.
Random digit dialling control subjects
From January 2002 until September 2004, a second control
group was recruited by using the random digit dialling
(RDD) method according to Waksberg [4]. RDD control
subjects between the age of 18 and 70 with no recent
history of deep venous thrombosis were included and the
same exclusion criteria were applied as for patients. The
RDD method has proved to be a suitable method that yields
a control group that can be regarded as approximating a
random sample of all individuals in the population [5].
For efficiency reasons, we frequency matched the RDD
control subjects to the patients who provided a blood
sample according to age and sex. With each telephone call
we asked a specific person within a household to partici-
pate depending on our needs to fill age and sex specific
strata (e.g. we asked for youngest woman between 20 and
50, or oldest man over age 50); this procedure also avoided
that the first person who picked up the phone was always
included as control subject.
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This procedure of control sampling was expensive and
time-consuming; on average only three control subjects per
hour were included. The response rate is known to be
dependent on demographic characteristics of the target
population and telephone skills of the interviewers [5]. In
addition the RDD method is only useful if the vast majority
of individuals live in households with a fixed (land-line)
telephone. In December 2005 fixed (land-line) telephone
coverage in the Netherlands was very high (96%) [6], indi-
cating that telephone coverage was sufficient for our RDD
method.
Data collection
Within a few weeks after diagnosis and registration at the
anticoagulation clinics patients with venous thrombosis
received a letter with information about the study and were
subsequently contacted by phone. Partners of patients were
also invited to participate. If patients or partners refused to
participate the reason for refusal was asked for. Patients,
partners and RDD control subjects received a standardized
questionnaire shortly after inclusion by phone. The ques-
tionnaires included items on potential risk factors for
venous thrombosis such as body weight, body height and
injuries. Most questions referred to a period of 12 months
prior to the index date, which was the date of venous
thrombosis for patients and the date of completing the
questionnaire for partners and RDD control subjects.
From March 1999 till June 2002, patients and their part-
ners were asked to visit the anticoagulation clinic at least
3 months after withdrawal of anticoagulation, where, after
an overnight fast, a blood sample was drawn. Only in case of
continuous use for more than 1 year a blood sample was
taken during anticoagulation therapy. From December 1999
onwards, self-administered buccal swabs were obtained by
mail when participants were unable or unwilling to provide a
blood sample. From June 2002 onwards, blood draws were
no longer performed in patients and their partners, and the
study was restricted to DNA collection by buccal swabs sent
by mail. RDD control subjects were invited for a blood draw
within a few weeks after they returned the questionnaire.
Within this group buccal swabs were sent when the blood
draw was refused. In the blood samples and buccal swabs
prothrombotic mutations including the Factor V Leiden
(G1691A) mutation were determined. A detailed description
of blood collection and DNA analysis for factor V Leiden in
the MEGA study has been published [7].
Different research questions, different use of control
subjects
To discuss the analytic considerations that arose from
having two different control groups we will describe the
association of a general lifestyle risk factor (body mass
index), an external risk factor (injuries), an example of a
genetic risk factor (factor V Leiden mutation), and an
analysis for the interaction between body mass index and
the factor V Leiden mutation—all with the risk of venous
thrombosis.
Results
Response rates and general characteristics
During the inclusion period, 5,961 eligible patients, 3,586
eligible partners and 4,346 eligible RDD control subjects
were approached to participate. In the patient group, 4,957
patients (83%) were willing to participate, partners had a
similar response rate (n = 2,917, 81%), and 3,000 (69%)
RDD control subjects participated (Fig. 1). Furthermore
DNA was available for 86.5% of the patients, 87.2% of the
partner control subjects and 67.4% of the RDD control
subjects. A possible explanation for this difference may be
that partners motivated each other to participate and were
able to join each other at the location of the blood draw.
General characteristics and reasons for non-response are
presented in Table 1.
Body mass index
When we investigated the BMI distribution in patients,
partners and the RDD control subjects, frequencies of
overweight (BMI: 25–29 kg/m2) and obesity (BMI:
C30 kg/m2) differed less between patients and their part-
ners than between patients and the RDD control subjects
[8]. This is most likely due to ‘assortative mating’ as well
as shared lifestyle over many years in couples, resulting in
lower risk estimates with the partner control group than
with the RDD control group. As these partners are matched
with patients (who are likely to be more obese, as obesity is
a risk factor for venous thrombosis), this matching has to
be considered in the statistical analysis [1]. In Table 2 the
result of the matched analysis (conditional logistic regres-
sion analysis) with patient-partner pairs is presented. Risk
estimates appeared to be still somewhat lower than in the
analysis with the RDD control subjects (overweightpartners
OR 1.45, CI95 1.26–1.67; overweightRDD OR 1.83, CI95
1.63–2.05; obesitypartners OR 1.81, CI95 1.49–2.20; obes-
ityRDD OR 2.87, CI95 2.45–3.35).
The use of the RDD control subjects in the analyses of
BMI as risk factor for venous thrombosis may result in a
slight overestimation of the true relative risk because of
selective inclusion: there were fewer RDD control subjects
with overweight than in the general Dutch population.
According to data of the Central Bureau of Statistics in the
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4346 eligible RDD 
control subjects 
3000 participants 
69% 
15 end stage disease 1331 refused to  
participate 
2789 returned questionnaire 
93%
1437 blood draws 
48%
586 buccal swabs 
20%
RDD CONTROL 
SUBJECTS 
5961 eligible patients: 
March 1999-June 2002: 3882  
June2002 -Sept2004:2079
4957 participants (a) 
83% 
82 end stage disease 922 refused to  
participate 
4543 returned  
questionnaire: 92% of a
March 1999-June 2002:
2350 blood draws: 73% of b
March 1999-June 2002:
425 buccal swabs:13% of b
June 2002-Sept 2004:  
1515 buccal swabs: 86% of c
March 1999-June 2002:
3202 (b) 
June 2002-Sept 2004:   
1755 (c) 
3586 eligible partners: 
March 1999-June 2002: 2318  
June2002 -Sept2004:1268
2917 participants (a) 
81.3% 
18 end stage disease 651 refused to  
participate 
2757 returned  
questionnaire: 95%of a
March 1999-June 2002:
1312 blood draws: 70%of b
March 1999-June 2002:
301 buccal swabs: 16% of b
June 2002-Sept 2004:  
931 buccal swabs: 89% of c
March 1999-June 2002:
1870 (b) 
June 2002-Sept 2004:  
1047 (c) 
 PARTNERS 
PATIENTS 
Fig. 1 Response rates of patients, partners and RDD control subjects
Table 1 Demographic
characteristics and reasons for
non-response in patients,
partners and RDD control
subjects
– Not an option provided to the
responders, * of participating
patients
Patients Partners RDD control
subjects
Responders (N) 4,957 2,917 3,000
Median age (5th–95th perc.) 48.6 (25.7–67.9) 48.3 (28.0–66.1) 45.3 (29.0–66.1)
Female sex (N, %) 2,682 (54.1) 1,464 (50.2) 1,719 (57.3)
Non-responders (N) 922 651* 1,331
No willingness (N, %) 607 (65.8) 628 (96.5) 1,243 (93.4)
Not mobile (N, %) 17 (1.8) 1 (0.2) –
Untraceable (N, %) 271 (29.3) 14 (2.2) 88 (6.6)
Filled in question-naire about recurrent
VT (N, %)
5 (0.5) – –
Reason unknown (N, %) 22 (2.4) 8 (1.2) –
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Netherlands the prevalence of overweight and obesity was
respectively 36 and 11% during the study period [9], while
we found 33 and 11% in the RDD group.
To obtain an overall effect estimate with a greater pre-
cision, we combined the matched and unmatched analyses
using an approach in which the estimates of the odds ratios
of the two analyses were pooled, taking into account that
most patients were in the analysis twice [10]. In this
combined analysis we accounted for the correlation
between the estimated odds ratios since most patients were
included both in the matched and the unmatched analysis.
Table 2 presents the odds ratios of the combined analysis
(ORoverweight 1.71, CI95 1.54–1.89, ORobesity 2.45, CI95
2.14–2.80), which were in-between the odds ratios for the
partner and RDD odds ratios.
The most likely explanation for the difference in risk
estimates between partners and RDD control subjects is
that the matched analysis will include adjustment for
measured as well as unmeasured confounders but also for
causal intermediary variables if those are related to couple
formation or shared lifestyles. Because of these additional
(over)adjustments the odds ratios in the partner analyses
could be closer to 1 than with the RDD control subjects.
However, the analysis of injuries as risk factor for venous
thrombosis proved that this is not always the case.
Injuries
We also studied the effect of minor injuries, such as con-
tusions and ankle sprains, on the risk of venous thrombosis
[11]. Minor injuries can be caused by occasional events
such as traffic accidents, but are also partly related to
lifestyle as for instance sports injuries will occur more
often in individuals with active lifestyles. Percentages of
injuries in the weeks before the index date are presented in
Fig. 2. Overall, patients had suffered from a minor injury in
11.7 percent in the 3 months prior to the venous throm-
bosis. Partners of patients had suffered from a minor injury
in 3.6 percent, while in RRD control subjects 4.8 percent
had had a minor injury. The odds ratios were 4.2 (CI95
2.9–6.0) with partner control subjects and 2.8 (CI95 2.3–
3.6) with RDD control subjects after adjustment for various
confounders, even after including sports activities, result-
ing in a combined estimate of 3.5 (CI95 2.8–4.3). These
risk estimates indicate that adjustment for confounders and
intermediates could also result in a higher risk estimate in
the matched analysis than in the unmatched analysis. It is
possible that RDD control subjects are spending more time
outdoors than partner control subjects, resulting in more
injuries than partners, because patients might have been
more sedentary (for example, patients with DVT are gen-
erally more obese), and therefore their partners might also
have been more sedentary—either by assortative mating or
a shared development of habits. Another possibility is
influence of the partners by the patients during the
answering of the questionnaire. As the patient has a serious
medical problem, namely thrombosis, the partner might not
want to complain about his or her relative minor injury,
resulting in a lower rate of (reported) minor injuries, and
therefore a higher risk estimate. Finally, active individuals
may be more likely to participate as controls than others.
Factor V Leiden
For genetic risk factors it seemed a priori unlikely that their
frequency is different in partners than in RDD control
subjects. However, the prevalence of factor V Leiden is
related to ethnicity [12] so one might speculate that if
partners chose their partner according to ethnicity the
factor V Leiden distribution in partners might become
different from RDD control subjects. In the MEGA study
most participants were of Dutch origin, so differences
between RDD control subjects and partner controls in the
distribution of factor V Leiden due to intra-racial partner-
ships were unlikely. For the RDD control subjects one
might hypothesize that RDD control subjects with a
Table 2 BMI as risk factor for venous thrombosis—Analyses with patients, partners and RDD control subjects
BMI (kg/m2) Patients N (%) Partners N (%) RDD N (%) ORpartner* (CI95) ORRDD* (CI95) ORcombined* (CI95)
Lean (\25) 1,369 (36.4%) 925 (44.0%) 1,409 (55.7%) 1 1 1
Overweight (25–29) 1,593 (42.4%) 860 (40.9%) 848 (33.5%) 1.45 (1.26–1.67) 1.83 (1.63–2.05) 1.71 (1.54–1.89)
Obese (C30) 794 (21.1%) 318 (15.1%) 274 (10.8%) 1.81 (1.49–2.20) 2.87 (2.45–3.35) 2.45 (2.14–2.80)
Total 3,756 2,103 2,531
Note BMI analyses were performed in non-pregnant individuals without malignancies
Adapted from [8]
ORpartner calculated with a matched analysis
ORRDD calculated with unconditional logistic regression
ORcombined calculated by the method of Le Cessie e.a. (2008)
*Adjusted for age and sex
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positive family history of venous thrombosis may be more
willing to give blood than RDD control subjects without a
positive family history, leading to an overestimation of the
prevalence of factor V Leiden in this group. This was found
not to be true as rates of positive family history were
similar in the two control groups and we found the same
percentage of individuals with factor V Leiden in the
partner and the RDD group. Obviously, both percentages
could be an overestimation of the true prevalence, but the
percentages were equal to the previously recorded preva-
lence of factor V Leiden in Caucasians [13].
Since both control groups had the same percentage of
factor V Leiden carriers and this percentage was supported
by literature, both control groups were combined as if they
were a single group in an unconditional logistic regression
analysis (Table 3).
BMI and factor V Leiden
The joint effect of overweight or obesity and the factor V
Leiden mutation [8] is presented as an example of the
analysis of gene-environment interaction. Since the anal-
yses of BMI required a combination of the matched anal-
yses when using partner control subjects and unconditional
logistic regression when using the RDD control subjects
[10], this approach was also used when analyzing the
combined effect of BMI and the factor V Leiden mutation
(Table 4). A disadvantage of using matched analyses when
studying interaction is that only discordant patient-partner
pairs can be included in the analyses resulting in small
numbers for those groups in which both exposures are
present (e.g. obese and factor V Leiden), as can be seen in
Table 4. When there are only a limited number of control
subjects, it is also possible to check for interaction using a
case-only analysis [14], which results in a multiplicative
synergy index [1]. This calculation of a multiplicative
synergy index [(1,077*124)/(217*643) = 0.96)] suggested
interaction at the multiplicative level and a tenfold
[(0.96*2.48*4.18 = 10.0)] increased risk for those being
obese and having the factor V Leiden mutation compared
with those being lean without factor V Leiden. This esti-
mation of the risk corresponds well with the 7.9 fold
increased risk that was found when combining the condi-
tional and unconditional regression analyses.
Discussion
In the MEGA study, a large population-based case–control
study, we collected two different control groups, a partner
control group and an RDD control group. Although for
each risk factor, the odds ratios were always in the same
direction and of the same order of magnitude with both
control groups, they were nevertheless different. Moreover,
when comparing several risk factors, it was not always the
same control group that produced the lower or higher
estimates, and a matched analysis did not completely annul
the differences.
We presented examples of analyses of different types of
research questions where we had to take decisions during
the analyses about how the results of the two control
groups could be combined. For the evaluation of body mass
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Fig. 2 Percentage of injuries
per week before the index date,
which was the diagnosis of
venous thrombosis (in patients)
or completion of the
questionnaire (in control
subjects). Adapted from [11]
Table 3 Factor V Leiden mutation (FVL) as risk factor for venous thrombosis—Analysis with patients, partners and RDD control subjects
FVL Patients N (%) Partners N (%) RDD N (%) ORpartner* (CI95) ORRDD* (CI95) ORtotal* (CI95)
- 3,612 (84.3%) 2,403 (94.7%) 1,914 (94.6%) 1 1 1
? 675 (15.7%) 134 (5.3%) 109 (5.4%) 3.38 (2.78–4.09) 3.36 (2.72–4.15) 3.36 (2.88–3.92)
Total 4,287 2,537 2,023
All ORs calculated with unconditional logistic regression
ORtotal calculated by pooling the two control groups
* Adjusted for age and sex
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index and the risk of minor injuries we used a method for
statistically combining the control groups in the analysis,
because for the partner control group a matched analysis
was required, which was neither necessary nor feasible in
the RDD group. For body mass index the RDD control
group produced somewhat higher risk estimates than
partner control subjects. However, this was not the case for
all analyses: for the analysis for the risk of minor injuries
the inverse was found, as RDD control subjects suffered
more injuries than partner control subjects. Finally, fre-
quencies of the factor V Leiden mutation, a genetic risk
factor, were identical in both control groups and indepen-
dent of lifestyles, indicating that for the analyses of this
genetic risk factor we could simply combine both control
groups. When studying the interaction between body mass
index and the factor V Leiden mutation the same statistical
approach was used as in the body mass index analyses.
An important aim of the MEGA study was to assess the
risk of venous thrombosis associated with the combination
of risk factors. When studying the interaction between a risk
factor specific to women and a lifestyle risk factor (e.g. the
joint effect of oral contraceptive use and BMI) it is not
straightforward to use a matched design with partner con-
trols. In this case, intuitively one might believe that it is not
possible to use the matched case–control design, because
only women are users of oral contraceptives and most
control subjects have the opposite sex as their matched
patients. However, after a publication from the MEGA study
it was suggested that one could think of being male as just a
reason for a person to be unexposed [15]. This should not
lead to exclusion of men from analyses of oral contraceptive
use (in the same way as it should not lead to exclusion of
women who are opposed to oral contraceptives for religious
or health reasons). When this idea was tried out on the
MEGA data, an analysis of oral contraceptive use and travel
with opposite sex controls proved not only possible but gave
more reliable results [16].
There are only a small number of studies reporting their
experience with multiple control groups. In 1983, Stavraky
and Clarke wrote a paper that summarized their experience
in using hospital and neighbourhood control subjects [17].
When testing the hypothesis whether oxidative hair dyes
were carcinogenic, they found lower rates of hair dye use
among 314 hospital (40.5%) than among 470 neighbour-
hood control subjects (52.8%). Several other differences
were observed. Compared with hospital control subjects,
neighbourhood control subjects were older, ethnically more
heterogeneous, less likely to be oral contraceptive users
and more likely to be smokers. The investigators believed
that most of these differences arose from different lifestyles
in the relatively rural region from which the hospital con-
trol subjects were derived and in the urban region that
provided the neighbourhood group. A study investigating
the association between machining fluid and laryngeal
cancer risk included control subjects with oral cancer as
well as a stratified random sample of all deaths in a distinct
geographical area as control subjects [18]. When cases
(n = 888) were compared to oral cancer control subjects
(n = 752) high exposure to machining fluids resulted in a
1.5-fold increased risk of laryngeal cancer. However, when
cases were compared with population control subjects
(n = 3,594) no increased risk of exposure was found. An
explanation, besides a chance finding, may be that data
quality on exposure for the cases and oral cancer control
subjects may have differed from that of the population
control subjects. These studies illustrate, paradoxically,
that if only one control group would have been included,
unrecognized bias might have influenced the results.
Besides differences in risk estimates also response rates
may vary between control groups. In the MEGA study
Table 4 Combined effect of body mass index and the factor V Leiden (FVL) mutation on the risk of venous thrombosis
BMI (kg/m2) FVL Patients N (%) Partners N (%) RDD N (%) ORpartner* ORRDD* ORcombined*
Lean - 1,077 (29.9%) 675 (41.7%) 956 (52.4%) 1 1 1
Overweight - 1,289 (35.8%) 664 (41.1%) 580 (31.8%) 1.40 (1.18–1.65) 1.92 (1.68–2.20) 1.72 (1.54–1.93)
Obese - 643 (17.9%) 229 (14.2%) 194 (10.6%) 1.78 (1.49–2.35) 2.88 (2.40–3.46) 2.48 (2.13–2.88)
Lean ? 217 (6.0%) 24 (1.5%) 45 (2.5%) 3.56 (2.32–6.41) 4.31 (3.09–6.02) 4.18 (3.12–5.61)
Overweight ? 250 (6.9%) 20 (1.2%) 38 (2.1%) 5.97 (3.24–11.00) 5.67 (3.98–8.08) 5.77 (4.20–7.93)
Obese ? 124 (3.4%) 5 (0.3%) 13 (0.7%) 6.15 (2.26–16.75) 8.48 (4.75–15.12) 7.86 (4.70–13.15)
Total 3,600 1,617 1,826
Adapted from [8]
ORpartner calculated with a matched analysis
ORRDD calculated with unconditional logistic regression
ORcombined calculated by the method of Le Cessie e.a. (2008)
* Adjusted for age and sex
 Only discordant couples provided information in this analyses and were included
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partner control subjects were more willing to participate
than RDD control subjects. An explanation for this dif-
ference may be that patients motivated their partners to
participate. Also the fact that partners of non-participating
patients were not included in the non-response may be an
explanation; if a patient refused to participate, we did not
ask the patients’ partner to participate. Thus a selection was
made of persons who were more willing to participate.
Selection bias could have occurred if RDD control
subjects would be more willing to participate if they had a
family member with thrombosis. However, there was no
difference between the control groups with respect to a
positive family history, nor between the prevalences of the
factor V Leiden mutation, suggesting a limited selection
bias in this respect. In contrast, at the start of the study we
assumed that pregnant partners or partners with a severe
disease such as cancer would be easier to recruit because of
a higher motivation than RDD control subjects with similar
characteristics. However, this was found not to be true as
RDD control subjects with a partner had even slightly
higher pregnancy rates than partners controls [19], and both
control groups had equal rates of cancer.
We are aware that most teaching in epidemiology
emphasises the choice of one control group. We deviated
from this, because we thought to have good reasons to do so.
Rosenbaum has suggested that it might be wise to include
two control groups which differ with respect to a covariate
that, though unmeasured, is know to differ substantially
between the two groups [20]. Similar outcomes in two such
control groups then provide evidence that imbalances in the
unmeasured covariate are not responsible for treatment-vs-
control differences in outcomes [20]. This was the case in
our study, as all odds ratios when using the partner or the
RDD control group were in the same direction. Still, some
differences in the behaviour of several variables between the
control groups were surprising. This gave us the opportunity
to study the effects of the choice for particular control
subjects: different choices for different control groups may
have consequences that may not always be anticipated
beforehand. Both control groups had very similar preva-
lences of the FVL mutation, and were therefore equally
suitable. When studying environmental or lifestyle risk
factors, however, no control group gave results that differed
in a predictable and systematic way from the other, and a
matched analyses did not solve the problem. In the end both
control groups had their own contribution.
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